Establish Effective Integrated Evidence Planning
Integrated Evidence Planning (IEP) enables pharma companies to address the evolving evidence needs of different external stakeholders throughout a product’s lifecycle. Effective IEP relies on a cross-functional team that owns the integrated evidence plan, to drive the delivery of compelling evidence generation and successfully influence decision-making by patients, physicians, and payers. Read the full one-page […]
Building a Medical Affairs Function
We recently interviewed Medical Affairs leaders in a range of pharma companies to discover how they build successful Medical Affairs functions. While companies structure their Medical Affairs teams differently based on their size and product portfolio, there are a number of common success factors to deliver the function’s key objective to lead evidence generation post-approval […]
Build an Agile CMC Function
In a recent project to optimise a pharma company’s Chemistry Manufacturing and Control (CMC) function, we interviewed CMC leaders to gain insight into how they have built effective CMC functions and how they measure success. They concurred that CMC functions must be agile and deliver on a range of projects while not impacting the critical […]
The Novasecta Annual MidPharma R&D Symposium 2025
On the 26th and 27th March 2025, we had the pleasure of hosting our annual face-to-face MidPharma R&D Symposium in London. The event began with a networking dinner on the evening of the 26th followed by facilitated discussions on the 27th. The symposium was attended by R&D Leaders from European-headquartered MidPharmas. We led discussions on […]
2025 R&D Symposium Insights: Manage Partnerships Successfully
On 26 and 27 of March 2025 we hosted our annual R&D Symposium in London, bringing together R&D leaders from pharmaceutical companies to discuss how they overcome important challenges in their organisations. Our final discussion focused on how R&D leaders manage partnerships to maximise value. R&D leaders form productive partnerships by aligning on responsibilities early […]
2025 R&D Symposium Insights: Allocate Resources Effectively
On 26th and 27th of March 2025 we hosted our annual R&D Symposium in London, bringing together R&D leaders from mid-sized pharmaceutical companies to discuss how they overcome important challenges in their organisations. The second of three discussions focused on how R&D leaders allocate resources to optimise the productivity of their organisations. R&D leaders allocate […]
2025 R&D Symposium Insights: Embed Project Centricity
On 26th and 27th of March we hosted our annual R&D Symposium in London, bringing together R&D leaders from mid-sized pharmaceutical companies to discuss how they overcome important challenges in their organisations. The first of three facilitated discussions focused on how R&D leaders embed project-centric ways of working within R&D. R&D leaders embed project centricity […]
Decision-making in Pharma
Decision-making is a key driver of strategic and operational excellence. Strategically and operationally excellent companies bringthe right people together at the right time, to make the key decisions that drive the organisation towards its goals. In this article, we apply our five-step strategic and operational excellence framework to decision-making. We share our view on how […]
Novasecta Networking Breakfasts
In 2024, Novasecta hosted two networking breakfasts for our pharmaceutical network in Copenhagen. The events were attended by senior representatives from a range of pharmaceutical companies, who brought diverse perspectives on the topics we discussed. On 9th April 2024, we discussed ‘Success in Pharma’, with a focus on how companies achieve long-term success through: […]
The Novasecta European MidPharma Report 2024
Europe is home to 98 ‘MidPharmas’: companies that research, develop, and commercialise pharmaceutical products with €100m-€10bn annual revenue. In our 2024 European MidPharma report, we examine the 2023 performance of European-headquartered MidPharmas and contrast it to Big Pharma. We then explore the success drivers that enable MidPharmas to thrive. What to Expect in the Report This year’s report […]